Not registered yet? Get a free account.
Sign UpYou're about to leave our website and go to an external link. Are you sure?
Mylan Laboratories Limited is a global pharmaceutical company that develops, manufactures, and delivers generic and specialty medications. It offers a diverse portfolio of over 1,400 generic and specialty products across various therapeutic areas, enabling access to high-quality healthcare for patients worldwide.
Mylan Laboratories Limited, is an unlisted public company incorporated on 29 November, 1984. It is classified as a public limited company and is located in , Telangana. It's authorized share capital is INR 125.00 cr and the total paid-up capital is INR 48.70 cr.
Read more
** All rupee values in INR crores. Based on March 2025 numbers.
* GST not included
** Reports & MCA filings will be based on the latest available financials.
** Delivery timelines are on best-effort basis during working hours. Filings 3-4 hours. Reports 24-48 hours.
* INR 349 for 20+ credits purchase
1 credit = one company dashboard
| State | Type | Address |
|---|
| Designation | Name | DIN/PAN | Tenure |
|---|---|---|---|
| Whole-time Director | Sarada Kalyani Bhagawati
Shareholder
|
02680074 | 12 years |
| Director | Rajiv Malik | 00120557 | 21 years |
| Director | Akshay Nanda | 10517236 | 2 years |
| Director | Ramya Suresh | 10603923 | 2 years |
| Additional Director | Arvind Shankar Kanda | 10560284 | 2 years |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Sales | 12,958.3 | 11,543.2 | 10,713.5 | 9,711.7 | 7,196.2 |
| Operating profit | 2,499.5 | 1,621.4 | 1,535.8 | 1,430.5 | -262.6 |
| Net profit | 1,112.3 | 642.8 | 480.3 | 259.7 | -954.3 |
| Gross margin | 51.9 | 51.6 | 57.7 | 49.6 | 41.8 |
| Operating margin | 19.3 | 14.1 | 14.3 | 14.7 | -3.6 |
| Net margin | 8.3 | 5.4 | 4.4 | 2.7 | -12.7 |
| Networth | 8,588.2 | 9,137.2 | 9,509.3 | 5,602.8 | 4,670.1 |
| Borrowings | 5,940.2 | 5,126.3 | 4,077.9 | 3,729.3 | 3,527.3 |
| Assets | 19,045.0 | 17,689.3 | 17,782.1 | 12,670.8 | 12,711.6 |
| Debt to equity | 0.7 | 0.6 | 0.4 | 0.7 | 0.8 |
| Current ratio | 2.8 | 2.5 | 2.2 | 2.7 | 2.5 |
| ROE | 12.9 | 7.0 | 5.0 | 4.6 | -20.4 |
| Days payable | 152.0 | 146.0 | 232.0 | 161.0 | 219.0 |
| WC days | 199.0 | 191.0 | 189.0 | 185.0 | 235.0 |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Equity Capital | 48.7 | 48.7 | 48.7 | 48.7 | 48.7 |
| Reserves | 8,539.5 | 9,088.5 | 9,460.6 | 5,554.1 | 4,621.4 |
| Borrowings + | 5,940.2 | 5,126.3 | 4,077.9 | 3,729.3 | 3,527.3 |
| Long term borrowings | 5,940.2 | 4,178.9 | 3,153.0 | 3,729.3 | 3,356.4 |
| Short term borrowings | - | 947.4 | 924.9 | - | 170.9 |
| Trade payables + | 2,586.3 | 2,230.3 | 2,884.5 | 2,156.3 | 2,513.1 |
| Days payable | 152.0 | 146.0 | 232.0 | 161.0 | 219.0 |
| Other liabilities + | 1,930.3 | 1,195.6 | 1,310.3 | 1,182.3 | 2,001.0 |
| Other non-current liabilities | 504.7 | 480.5 | 455.8 | 464.2 | 1,492.8 |
| Other current liabilities | 1,425.6 | 715.0 | 854.5 | 718.1 | 508.2 |
| Total liabilities | 19,045.0 | 17,689.3 | 17,782.1 | 12,670.8 | 12,711.6 |
| Fixed Assets + | 7,441.2 | 6,952.8 | 6,712.1 | 4,174.5 | 4,386.2 |
| Tangible assets | 4,344.9 | 4,251.2 | 4,722.9 | 3,087.1 | 3,421.0 |
| CWIP | 369.1 | 609.1 | 525.9 | 712.4 | 663.1 |
| Intangible assets | 2,727.2 | 2,092.4 | 1,463.2 | 375.0 | 302.0 |
| LT loans and advances | - | - | - | - | - |
| Other non-current assets | 539.5 | 814.6 | 853.2 | 698.9 | 495.3 |
| Current assets + | 11,064.3 | 9,922.0 | 10,216.7 | 7,797.3 | 7,830.1 |
| Inventories | 4,538.0 | 4,910.1 | 5,421.9 | 3,309.8 | 4,720.4 |
| Trade receivables | 5,013.0 | 3,914.8 | 3,945.2 | 3,631.0 | 2,438.8 |
| Cash and cash equivalents | 65.3 | 37.3 | 5.2 | 126.2 | 23.9 |
| ST loans and advances | 242.1 | 242.1 | - | - | - |
| Other current assets | 1,206.0 | 817.7 | 844.4 | 730.3 | 647.1 |
| Total assets | 19,045.0 | 17,689.3 | 17,782.1 | 12,670.8 | 12,711.6 |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Sales + | 12,958.3 | 11,543.2 | 10,713.5 | 9,711.7 | 7,196.2 |
| Sales growth % | 5.88 | -10.92 | -7.19 | -9.35 | -25.9 |
| Expenses + | 12,465.9 | 11,526.6 | 10,509.5 | 9,270.3 | 8,363.2 |
| Cost of goods | 6,230.2 | 5,591.6 | 4,535.8 | 4,892.4 | 4,185.6 |
| Employee cost | 1,433.3 | 1,471.4 | 1,577.9 | 1,414.5 | 1,480.3 |
| Other costs | 2,795.3 | 2,858.8 | 3,064.0 | 1,974.4 | 1,792.9 |
| Operating profit + | 2,499.5 | 1,621.4 | 1,535.8 | 1,430.5 | -262.6 |
| Operating margin % | 19.3 | 14.1 | 14.3 | 14.7 | -3.6 |
| Other income | 479.9 | 457.7 | 241.5 | 50.0 | 307.4 |
| Interest | 744.3 | 550.8 | 239.0 | 413.1 | 379.1 |
| Depreciation | 1,262.9 | 1,054.0 | 1,092.8 | 576.0 | 525.4 |
| Exceptional items | - | - | - | - | - |
| Profit before tax | 972.3 | 474.4 | 445.5 | 491.4 | -859.7 |
| Tax | -140.0 | -168.4 | -34.8 | 85.2 | 94.6 |
| Profit - disc. ops | - | - | - | -146.5 | - |
| Net profit | 1,112.3 | 642.8 | 480.3 | 259.7 | -954.3 |
| Net margin % | 8.3 | 5.4 | 4.4 | 2.7 | -12.7 |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Solvency + | |||||
| Total Debt/Equity | 0.7 | 0.6 | 0.4 | 0.7 | 0.8 |
| Net Debt/Equity | 0.7 | 0.6 | 0.4 | 0.6 | 0.8 |
| Total Debt/Assets | 0.3 | 0.3 | 0.2 | 0.3 | 0.3 |
| Total Assets/Equity | 2.2 | 1.9 | 1.9 | 2.3 | 2.7 |
| Liquidity + | |||||
| Current Ratio | 2.8 | 2.5 | 2.2 | 2.7 | 2.5 |
| Quick Ratio | 1.6 | 1.3 | 1.0 | 1.6 | 1.0 |
| Interest Coverage | 3.4 | 2.9 | 6.4 | 3.5 | -0.7 |
| Performance | |||||
| Gross Margin | 51.9 | 51.6 | 57.7 | 49.6 | 41.8 |
| Operating Margin | 19.3 | 14.1 | 14.3 | 14.7 | -3.6 |
| Net Margin | 8.3 | 5.4 | 4.4 | 2.7 | -12.7 |
| Return + | |||||
| Return on Equity | 12.9 | 7.0 | 5.0 | 4.6 | -20.4 |
| Pre-tax ROCE | 8.5 | 4.4 | 3.6 | 9.4 | -8.7 |
| Return on Assets | 5.8 | 3.6 | 2.7 | 2.0 | -7.5 |
| Pre-tax ROIC | 8.6 | 4.0 | 3.3 | 9.3 | -9.6 |
| Efficiency + | |||||
| Days Payable | 152.0 | 146.0 | 232.0 | 161.0 | 219.0 |
| Days Inventory | 266.0 | 321.0 | 436.0 | 247.0 | 412.0 |
| Days Receivable | 141.0 | 124.0 | 134.0 | 136.0 | 124.0 |
| Fixed Asset Turnover | 1.7 | 1.7 | 1.6 | 2.3 | 1.6 |
| Total Asset Turnover | 0.7 | 0.7 | 0.6 | 0.8 | 0.6 |
| Working Capital | |||||
| Cash Conversion Cycle | 255.0 | 299.0 | 338.0 | 222.0 | 317.0 |
| Working Capital Days | 199.0 | 191.0 | 189.0 | 185.0 | 235.0 |
As per information available, the company has no registered charges.
| Name | Status | Paid up Capital | Common Directors | Address |
|---|---|---|---|---|
| BIOCON BIOLOGICS LIMITED |
Active
|
1,758.3 Cr | 1 | Karnataka |
| RAPIDUE TECHNOLOGIES PRIVATE LIMITED |
Active
|
19.2 Cr | 1 | Telangana |
| ASTRIX LABORATORIES LIMITED |
Amalgamated
|
4.5 Cr | 1 | Telangana |
| MADAUS PHARMACEUTICALS PRIVATE LIMITED |
Amalgamated
|
33.0 Cr | 1 | Telangana |
| JAI PHARMA LIMITED |
Amalgamated
|
1.7 Cr | 1 | Maharashtra |
| Name | State / Country | Incorporation Year | Paidup Capital |
|---|---|---|---|
| Famy Care Europe Limited | United Kingdom | - | - |
Read more
The incorporation date of MYLAN LABORATORIES LIMITED is 29 November, 1984
The authorized share capital of MYLAN LABORATORIES LIMITED is INR ₹ 125.0 Cr.
The paid-up capital of MYLAN LABORATORIES LIMITED is INR ₹ 48.7 Cr.
The registered address of MYLAN LABORATORIES LIMITED is Plot No.564/A/22 Road No.92 Jubilee Hills, Hyderabad, Hyderabad, Telangana, India, 500096 - 500096
The CIN number of MYLAN LABORATORIES LIMITED is U24231TG1984PLC005146.